During the president’s first term, pharmaceutical imports were excluded from such taxes, but the Trump administration is now attempting to levy duties on them.
Prices may eventually rise as a result of the tariffs, which may worsen shortages of some medications, especially generic ones.
Medicare and its beneficiaries may save money if the new presidential order is similar to the 2020 regulation.
However, experts warned that it might also restrict patients’ access to prescription drugs. The structure of the policy determines a lot.
Trump’s assertion that his most recent initiative would significantly lower prescription costs was refuted by at least one health care policy researcher.
Chris Meekins, a Raymond James analyst, wrote in a note to clients Sunday night, “Trump has a long history in his first term of talking bigger on drug pricing than what his policies would actually do.”
“Trump’s proposed executive actions are less likely to be carried out the more extravagant they are, as successful court challenges will be far more likely.”
